Pros | - | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | - | 1/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 3 Years | 12 Years | ||
Fund Size | 214 Cr | 3611 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹500 Lumpsum ₹5000 | ||
Expense Ratio | 0.47% | 0.9% | ||
Exit Load | 1% | 0.5% | ||
Benchmark Index | Nifty Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 40 | 32 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (16.22%) Divi's Laboratories Ltd (5.96%) Lupin Ltd (5.78%) Suven Pharmaceuticals Ltd (5.39%) Apollo Hospitals Enterprise Ltd (5.16%) | Sun Pharmaceuticals Industries Ltd (13.45%) Max Healthcare Institute Ltd Ordinary Shares (6.68%) Divi's Laboratories Ltd (6%) Cipla Ltd (4.79%) Lupin Ltd (4.72%) | ||
No of Sectors | 3 | 2 | ||
Top 3 Sectors | Health (95.43%) Basic Materials (3.54%) Industrial (1.03%) | Health (93.19%) Basic Materials (6.81%) | ||
Equity % | 97.95% | 96.96% | ||
Debt % | - | - | ||
P/E | 37.64 | 42.28 | ||
P/B | 5.87 | 5.85 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 2.51% | 0.11% | ||
3-Month Return | 4.89% | 1.1% | ||
6-Month Return | -3.53% | 2.29% | ||
1-Year Return | 20.01% | 22.26% | ||
3-Year Return | 21.39% | 25.03% | ||
5-Year Return | - | 25.82% |
Sharpe | 0.84 | 1.12 | ||
Alpha | 2.89 | 5.03 | ||
Beta | 0.91 | 0.85 | ||
Standard Deviation | 16.41 | 14.93 | ||
Information Ratio | 0.51 | 1 |
Description | ITI Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | SBI Healthcare Opportunities Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | - | Tanmaya Desai |